V. A pharmaceutical composition for treating glaucoma, the composition comprising an effective amount of the compound of any one of Paragraphs A-I and a pharmaceutically acceptable excipient.

W. The pharmaceutical composition of Paragraph V, wherein the glaucoma is myocilin glaucoma.

X. The pharmaceutical composition of Paragraph V or Paragraph W, wherein the pharmaceutical composition is packaged in unit dosage form.

Y. A method of inhibiting death of a cell exhibiting mutant myocilin, the method comprising contacting the cell with a compound of any one of Paragraphs A-I.

Z. The method of Paragraph Y, wherein the method comprises contacting the cell with an effective amount of the compound.

AA. The method of Paragraph Y or Paragraph Z, wherein the contacting inhibits the death of the cell in comparison to a cell exhibiting mutant myocilin that is not contacted with the compound.

BA. A method of treating a patient or animal suffering from glaucoma, the method comprising administration of an effective amount of a compound of any one of Paragraphs A-I to the patient or animal suffering from the glaucoma.

CA. The method of Paragraph BA, wherein administration of the effective amount of the compound to the patient or animal treats the patient or animal suffering from the cancer or the glaucoma.

DA. The method of Paragraph BA or Paragraph CA, wherein the glaucoma is myocilin glaucoma.

[0277] Other embodiments are set forth in the following claims, along with the full scope of equivalents to which such claims are entitled.

1. A compound of Formula I



(I)

or a pharmaceutically acceptable salt thereof, wherein

X^1 is Cl or F;

X^2 is CH_2 or O;

R^1, R^2, R^4, R^5, and R^6 are each independently H, alkoxy, hydroxyl, thiol, or halo; and

R^3 is H, alkoxy, amino, hydroxyl, thiol, or halo.

2. The compound of claim **1**, wherein the compound is



,



,



,



,



,